Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 3/20 | 0.59 |
| ▸ | HRH1 | P35367 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523557 | 1.00 | HRH2 (0.59) | HRH2HRH1KMT2AMAPK1P2RX7 | |
| SCHEMBL693690 | 0.90 | P2RX7 (0.57) | HRH2HRH1KMT2AMAPK1P2RX7 | |
| SCHEMBL719186 | 0.90 | P2RX7 (0.57) | HRH2HRH1KMT2AMAPK1P2RX7 | |
| SCHEMBL3330129 | 0.88 | P2RY12 (0.50) | HRH2HRH1P2RX7P2RY12 | |
| SCHEMBL3330120 | 0.88 | P2RY12 (0.50) | HRH2HRH1P2RX7P2RY12 | |
| SCHEMBL16466268 | 0.88 | P2RX7 (0.63) | HRH2HRH1KMT2AMAPK1P2RX7 | |
| SCHEMBL20612380 | 0.88 | P2RX7 (0.63) | HRH2HRH1KMT2AMAPK1P2RX7 | |
| SCHEMBL16466473 | 0.88 | P2RX7 (0.63) | HRH2HRH1KMT2AMAPK1P2RX7 | |
| SCHEMBL3330097 | 0.86 | P2RY12 (0.47) | HRH2HRH1KMT2AP2RY12 | |
| SCHEMBL3330092 | 0.86 | P2RY12 (0.47) | HRH2HRH1KMT2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417128-B1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-02 | — | — | EP | disclosed |
| US-8288385-B2 | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | P2RY12, P2RY13, P2RY6 | HRH2 305/4885HRH1 643/4885KMT2A 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.